Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Viking Therapeutics Inc Market Cap
Based on ratings from 15 stock analysts, the Viking Therapeutics Inc stock price is expected to increase by 129.89% in 12 months. This is calculated by using the average 12-month stock price forecast for Viking Therapeutics Inc. The lowest target is $74 and the highest is $164. Please note analyst price targets are not guaranteed and could be missed completely.
Viking Therapeutics Inc has a total of 15 Wall St Analyst ratings. There are 15 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Viking Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of VKTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Biren Amin Piper Sandler | Overweight | $74 | Initiates | Dec 2, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $102 | Reiterates | Nov 27, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $102 | Reiterates | Nov 26, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $109 | Initiates | Nov 22, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $102 | Maintains | Nov 5, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Oct 24, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Oct 9, 2024 |
| Jay Olson Oppenheimer | Outperform | $138 | Reiterates | Sep 25, 2024 |
| Michael Ulz Morgan Stanley | Overweight | $105 | Reiterates | Sep 12, 2024 |
| Hardik Parikh JP Morgan | Overweight | $80 | Initiates | Sep 11, 2024 |
| Steven Seedhouse Raymond James | Strong Buy | $118 | Maintains | Jul 25, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Jul 25, 2024 |
| Michael Ulz Morgan Stanley | Overweight | $105 | Initiates | Jun 27, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Jun 24, 2024 |
| Joon Lee Truist Securities | Buy | $120 | Maintains | Jun 17, 2024 |
| Steven Seedhouse Raymond James | Strong Buy | Reiterates | Jun 4, 2024 | |
| Naz Rahman Maxim Group | Buy | $120 | Reiterates | Jun 4, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Jun 4, 2024 |
| Joon Lee Truist Securities | Buy | $120 | Reiterates | May 16, 2024 |
| Steven Seedhouse Raymond James | Strong Buy | $116 | Upgrade | May 16, 2024 |
When did it IPO
2015
Staff Count
30
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Brian Lian Ph.D.
Market Cap
$5.33B
In 2023, VKTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that VKTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Dec 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - A healthcare stock has experienced significant growth due to positive news, including successful trial results for a weight loss candidate, a key growth sector this year.
Why It Matters - Positive trial results for a weight loss candidate can drive stock prices higher, indicating strong growth potential and investor interest in the healthcare sector.
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Viking Therapeutics' VK2735 shows promise in the GLP-1 obesity drug market, potentially competing with Eli Lilly's Zepbound and Novo Nordisk's Wegovy, pending pivotal study approval.
Why It Matters - Viking Therapeutics' VK2735 could disrupt the GLP-1 obesity drug market, potentially affecting shares of Eli Lilly and Novo Nordisk if it proves superior in pivotal studies and approval.
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - The Motley Fool
Summary - Pfizer (PFE) continues to face challenges with declining sales of its coronavirus products and subpar financial results over the past two years.
Why It Matters - Pfizer's declining sales from coronavirus products and poor financial performance may signal ongoing challenges, affecting stock value and investor confidence in future growth.
Tue, 03 Dec 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Viking Therapeutics (VKTX) is developing a promising GLP-1 weight loss treatment, with potential to significantly boost revenue as competition in the space increases.
Why It Matters - The entry of companies into the GLP-1 drug market, including Viking Therapeutics, signals potential high revenue growth and competitive dynamics, impacting stock valuations and investment strategies.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Pomerantz LLP is investigating claims for investors of Viking Therapeutics, Inc. (NASDAQ: VKTX). Interested investors can contact Danielle Peyton for more information.
Why It Matters - The investigation into Viking Therapeutics may indicate potential legal issues or financial mismanagement, which could affect stock performance and investor confidence.
Tue, 03 Dec 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Since the presidential election, small-cap stocks have gained traction, with the Russell 2000 index outperforming the S&P 500 by 3.4% as of November 29, 2024.
Why It Matters - Small-cap stocks are outperforming larger ones post-election, signaling potential shifts in market sentiment and investment strategies, which can influence portfolio allocations and risk assessments.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
